Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2022
April 19, 2022 at 08:45 am EDT
Share
Zhejiang Jolly Pharmaceutical Co.,LTD reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 439.42 million compared to CNY 340.16 million a year ago. Revenue was CNY 439.42 million compared to CNY 340.16 million a year ago. Net income was CNY 68.75 million compared to CNY 43.8 million a year ago. Basic earnings per share from continuing operations was CNY 0.113 compared to CNY 0.072 a year ago. Diluted earnings per share from continuing operations was CNY 0.113 compared to CNY 0.072 a year ago.
Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Companyâs main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD 
